Skip to main content

Table 1 Patients’ demographic data and anemia status at transplant and at each year of follow-up

From: Prevalence and management of post-transplant anemia in long-term follow-up of Chinese kidney transplant recipients: a single-center report

Year post-transplant 0 1 2 3 4 5
Total (n) 154 140 136 128 126 118
Age (years) 38.1 ± 10.3 38.8 ± 10.4 39.9 ± 10.4 40.0 ± 9.9 41.1 ± 9.9 41.9 ± 10.0
Gender (male/female) 109/45 98/42 97/39 89/39 89/37 85/33
Immunosuppressive
CsA + AZT + pred 30 (19.5%) 25 (17.9%) 20 (14.7%) 17 (13.3%) 16 (12.7%) 14 (11.9%)
CsA + MMF + pred 89 (57.8%) 81 (58.6%) 84 (61.8%) 80 (62.5%) 79 (62.7%) 73 (61.9%)
Tac + MMF + pred 32 (20.8%) 31 (22.1%) 30 (22.1%) 29 (22.7%) 29 (23.0%) 29 (24.6%)
Tac + AZT + pred 3 (1.9%) 2 (2%) 2 (1.5%) 2 (1.6%) 2 (1.6%) 2 (1.7%)
Mean Hb (g/dL) 11.5 ± 1.5 13.7 ± 1.9 13.7 ± 1.8 13.5 ± 1.9 13.4 ± 1.9 13.0 ± 2.0
Anemic
n 70 15 13 19 17 23
Percentage 45.5% 10.7% 9.6% 14.8% 13.5% 19.6%
  1. AZT, azathioprine; CsA, cyclosporin A; Hb, hemoglobin; MMF, mycophenolate mofetil; pred, prednisone; Tac, tacrolimus.